ArticleOncoimmunology
Regulation of NKG2D
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses.Cancer immunology, immunotherapy : CII · 2023Article
- Cellular rejuvenation: molecular mechanisms and potential therapeutic interventions for diseases.Signal transduction and targeted therapy · 2023Review
- The metabolism of cells regulates their sensitivity to NK cells depending on p53 status.Scientific reports · 2022Article
- Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- CD80 expression is upregulated by TP53 activation in human cancer epithelial cells.Oncoimmunology · 2021Article
- Lysine acetylation of NKG2D ligand Rae-1 stabilizes the protein and sensitizes tumor cells to NKG2D immune surveillance.Cancer letters · 2021Article
- The untwining of immunosenescence and aging.Seminars in immunopathology · 2020Review
- Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.Cancer science · 2020Article
- Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.Frontiers in immunology · 2020Article
- A VEGFR2-MICA bispecific antibody activates tumor-infiltrating lymphocytes and exhibits potent anti-tumor efficacy in mice.Cancer immunology, immunotherapy : CII · 2019Article
- STAT3, a Master Regulator of Anti-Tumor Immune Response.Cancers · 2019Review
- Epithelial CD80 promotes immune surveillance of colonic preneoplastic lesions and its expression is increased by oxidative stress through STAT3 in colon cancer cells.Journal of experimental & clinical cancer research : CR · 2019Article
- An immunoproteomic approach to characterize the CAR interactome and signalosome.Science signaling · 2019Article
- Immunonutritional consequences of different serine-type protease inhibitors in a C57BL/6 hepatocarcinoma model.Oncotarget · 2019Article
- Senescent cell clearance by the immune system: Emerging therapeutic opportunities.Seminars in immunology · 2018Review
- Functions of NKG2D in CD8Cellular & molecular immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The natural killer (NK) group 2D (NKG2D) receptor, which displays on mouse and human NK cells, activates CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.